Acquiring Company
Processa Pharmaceuticals
Acquired Company
Vidya Therapeutics
HanoverHealthcareBiotechnologyHealth CareDescription
On October 5, 2026, Processa Pharmaceuticals finalized the acquisition of Vidya Therapeutics, Inc. This acquisition was initially disclosed on July 29, 2026, and included comprehensive financial statements. The merger agreement was executed on July 28, 2026, involving multiple entities. This amendment also covers updates to business operations and risk factors post-acquisition.
Fundz sees it the moment Processa Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Vidya Therapeutics?
Vidya Therapeutics was acquired by Processa Pharmaceuticals, based in Hanover. The deal was reported on October 5, 2026. Processa Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with unmet medical needs. Processa Pharmaceuticals is publicly traded (PCSA) and operates in Healthcare.
When did Processa Pharmaceuticals acquire Vidya Therapeutics?
Processa Pharmaceuticals's acquisition of Vidya Therapeutics was reported on October 5, 2026. On October 5, 2026, Processa Pharmaceuticals finalized the acquisition of Vidya Therapeutics, Inc. This acquisition was initially disclosed on July 29, 2026, and included comprehensive financial statements. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Vidya Therapeutics do?
Vidya Therapeutics is a clinical-stage biotech company developing innovative drugs targeted towards immune-mediated disorders. Its main asset includes a novel BTK inhibitor designed for various applications in immunology. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.